In the presented work, amphiphilic nanoparticles based on chitosan and carboxy-enriched polylactic acid have been prepared to improve the stability of the pro-drug temozolomide in physiological media by encapsulation. The carrier, with a diameter in the range of 150-180 nm, was able to accommodate up to 800 μg of temozolomide per mg of polymer. The obtained formulation showed good stability in physiological condition and preparation media up to 1 month. Temozolomide loaded inside the carrier exhibited greater stability than the free drug, in particular in simulated physiological solution at pH 7.4 where the hydrolysis in the inactive metabolite was clearly delayed. CS-SPLA nanoparticles demonstrated a pH-dependent TMZ release kinetics with the opportunity to increase or decrease the rate. Mass spectroscopy, UV-Vis analysis, and in vitro cell tests confirmed the improvement in temozolomide stability and effectiveness when loaded into the polymeric carrier, in comparison with the free drug.

Centre of Polymer Systems University Institute Tomas Bata University in Zlín tr T Bati 5678 76001 Zlin Czech Republic

See more in PubMed

Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58(15):1688–1713. doi: 10.1016/j.addr.2006.09.017. PubMed DOI

Abdelwahed W, Degobert G, Fessi H. A pilot study of freeze drying of poly (epsilon-caprolactone) nanocapsules stabilized by poly (vinyl alcohol): formulation and process optimization. Int J. 2006;309(1):178–188. PubMed

Abdelwahed W, Degobert G, Fessi H. Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. Eur J Pharm and Biopharm. 2006;63(2):87–94. doi: 10.1016/j.ejpb.2006.01.015. PubMed DOI

Agarwala SS, Kirkwood JM. Promising new drugs and combinations. Oncologist. 2000;5:144–151. doi: 10.1634/theoncologist.5-2-144. PubMed DOI

Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5(2):144–151. doi: 10.1634/theoncologist.5-2-144. PubMed DOI

Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumours. Biomaterials. 2009;30(12):2302–2318. doi: 10.1016/j.biomaterials.2009.01.003. PubMed DOI

Ananta SJ, Paulmurugan R, Massoud TF. Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation. Neurol Res. 2016;38(1):51–59. doi: 10.1080/01616412.2015.1133025. PubMed DOI

Appel EA, Rowland MJ, Loh XJ, Heywood RM, Watts C, Scherman OA. Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit [n] uril. Chem Comm. 2012;48(79):9843–9845. doi: 10.1039/c2cc35131e. PubMed DOI

Bajpai AK, Anjali G (2003) Water sorption behavior of highly swelling (carboxy methylcellulose-gpolyacrylamide) hydrogels and release of potassium nitrate as agrochemical. Carbohydr Polym 53(3):271-279

Bajpai J, Maan GK, Bajpai AK. Preparation, characterization and water uptake behavior of polysaccharide based nanoparticles: swelling behaviour of nanoparticles. Prog Nanotech Nanomater. 2012;1:9–17.

Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, Donehower RC. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res. 1999;5(2):309–317. PubMed

Bowman K, Leong KW (2006) Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 1(2):117-128 PubMed PMC

Cho K, Wang XU, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310–1316. doi: 10.1158/1078-0432.CCR-07-1441. PubMed DOI

Chowdhury SK, Laudicina D, Blumenkrantz N, Wirth M, Alton KB. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma. J Pharmaceut Biomed. 1999;19(5):659–668. doi: 10.1016/S0731-7085(98)00198-8. PubMed DOI

Darkes MJ, Plosker GL, Jarvis B. Temozolomide. Am J Cancer. 2002;1(1):55–80. doi: 10.2165/00024669-200201010-00006. DOI

Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochem 33(31):9045-9051 PubMed

Di Martino A, Sedlarik V. Amphiphilic chitosan-grafted-functionalized polylactic acid based nanoparticles as a delivery system for doxorubicin and temozolomide co-therapy. Int J Pharm. 2014;474(1):134–145. doi: 10.1016/j.ijpharm.2014.08.014. PubMed DOI

Di Martino A, Kucharczyk P, Zednik J, Sedlarik V. Chitosan grafted low molecular weight polylactic acid for protein encapsulation and burst effect reduction. Int J Pharm. 2015;496(2):912–921. doi: 10.1016/j.ijpharm.2015.10.017. PubMed DOI

Di Martino A, Pavelkova A, Maciulyte S, Budriene S, Sedlarik V. Polysaccharide-based nanocomplexes for co-encapsulation and controlled release of 5-fluorouracil and temozolomide. Eur J Pharm Sci. 2016;92:276–286. doi: 10.1016/j.ejps.2016.05.001. PubMed DOI

Dresemann G. Temozolomide in malignant glioma. Onco Targets Ther. 2010;3:139–146. doi: 10.2147/OTT.S5480. PubMed DOI PMC

Drumright RE, Gruber PR, Henton DE. Polylactic acid technology. Advanced Mmaterials. 2000;12(23):1841–1846. doi: 10.1002/1521-4095(200012)12:23<1841::AID-ADMA1841>3.0.CO;2-E. DOI

El-Sharief AMS, Al-Amri AM, Al-Raqa SY. Halogenated, alkylated and new types of imidazolidine, pyrrolidine, imidazotriazine and thienoimidazole derivatives with biological and antitumor activities. J Sulfur Chem. 2006;27(03):245–263. doi: 10.1080/17415990600631316. DOI

Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Del. 2007;4(4):403–416. doi: 10.1517/17425247.4.4.403. PubMed DOI

Fiore D, Jackson AJ, Didolkar MS, Dandu VR. Simultaneous determination of dacarbazine, its photolytic degradation product, 2-azahypoxanthine, and the metabolite 5-aminoimidazole-4-carboxamide in plasma and urine by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1985;27(6):977–979. doi: 10.1128/AAC.27.6.977. PubMed DOI PMC

Gasmi H, et al. Does PLGA microparticle swelling control drug release? New insight based on single particle swelling studies. J Control Release. 2015;213:120–127. doi: 10.1016/j.jconrel.2015.06.039. PubMed DOI

Ge W, Li D, Chen M, Wang X, Liu S, Sun R. Characterization and antioxidant activity of β-carotene loaded chitosan-graft-poly (lactide) nanomicelles. Carbohydr Polym. 2015;117:169–176. doi: 10.1016/j.carbpol.2014.09.056. PubMed DOI

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Bromberg JE. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003. doi: 10.1056/NEJMoa043331. PubMed DOI

Huang S, Wan Y, Wang Z, Wu J. Folate-conjugated chitosan–polylactide nanoparticles for enhanced intracellular uptake of anticancer drug. JNR. 2013;15(12):1–15.

Jain DS, Athawale RB, Bajaj AN, Shrikhande SS, Goel PN, Nikam Y, Gude RP (2014) Unraveling the cytotoxic potential of Temozolomide loaded into PLGA nanoparticles. DARU 22(1):18 PubMed PMC

Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE (2001). 5'-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem 14, 276, 50, 46912–46916 PubMed

Jeyarama AS, Paulmurugan R, Tarik FM (2016) Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation. Neurol Res 38(1):51-59 PubMed

Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today. 2008;13(23):1099–1106. doi: 10.1016/j.drudis.2008.09.005. PubMed DOI

Kim H, Likhari P, Parker D, Statkevich P, Marco A, Lin CC, Nomeir AA. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Biomed Anal. 2001;24(3):461–468. doi: 10.1016/S0731-7085(00)00466-0. PubMed DOI

Koo YEL, Reddy GR, Bhojani M, Schneider R, Philbert MA, Rehemtulla A, Kopelman R. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliver Rev. 2006;58(14):1556–1577. doi: 10.1016/j.addr.2006.09.012. PubMed DOI

Kucharczyk P, Zednik J, Sedlarik V (2016). Star-shaped carboxyl group functionalized poly(lactic) prepared through polycondensation reaction. Submitted fopr publication to Macromolecular chemistry and Physics 2016- Under revision

Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18. doi: 10.1016/j.colsurfb.2009.09.001. PubMed DOI

Lagona J, Mukhopadhyay P, Chakrabarti S, Isaacs L. The cucurbit [n] uril family. AngewChem Int Ed. 2005;44(31):4844–4870. doi: 10.1002/anie.200460675. PubMed DOI

Lanz-Landázuri A, García-Alvarez M, Portilla-Arias J, Martínez de Ilarduya A, Patil R, Holler E, Muñoz-Guerra S. Poly (methyl malate) nanoparticles: formation, degradation, and encapsulation of anticancer drugs. Macromol Biosci. 2011;11(10):1370–1377. doi: 10.1002/mabi.201100107. PubMed DOI PMC

Lazzari S, Moscatelli D, Codari F, Salmona M, Morbidelli M, Diomede L. Colloidal stability of polymeric nanoparticles in biological fluids. JNR. 2012;14(6):1–10. PubMed PMC

Ling Y, Wei K, Zou F, Zhong S. Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. Int J Pharm. 2012;430(1):266–275. doi: 10.1016/j.ijpharm.2012.03.047. PubMed DOI

Lopes IC, de Oliveira SCB, Oliveira-Brett AM. Temozolomide chemical degradation to 5-aminoimidazole-4-carboxamide–electrochemical study. J Electroanal Chem. 2013;704:183–189. doi: 10.1016/j.jelechem.2013.07.011. DOI

Lu W, Sun Q, Wan J, She Z, Jiang XG. Cationic albumin–conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res. 2006;66(24):11878–11887. doi: 10.1158/0008-5472.CAN-06-2354. PubMed DOI

Matosiuk D, Fidecka S, Antkiewicz-Michaluk L, Lipkowski J, Dybala I, Koziol AE. Synthesis and pharmacological activity of new carbonyl derivatives of 1-aryl-2-iminoimidazolidine: part 2. Synthesis and pharmacological activity of 1, 6-diaryl-5, 7 (1H) dioxo-2, 3-dihydroimidazo [1, 2-a][1, 3, 5] triazines. Eur J Med Chem. 2002;37(9):761–772. doi: 10.1016/S0223-5234(02)01408-3. PubMed DOI

McCarron PA, Hall M (2004) Pharmaceutical nanotechnology. Encycl Nanosci Nanotechnol 8:469-487

Meer L, Janzer RC, Kleihues P, Kolar GF. In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) Biochem Pharmacol. 1986;35(19):3243–3247. doi: 10.1016/0006-2952(86)90419-3. PubMed DOI

Mehare G, Sengodan T, Tamizharasi S, Sivakumar T, Sawarkar S, Piyush CP (2015) Formulation and characterization of pla nanoparticles of temozolomide. EJPMR 2(5):1089-1100

Nygren H, Eksborg S. Stability of temozolomide in solutions aimed for oral treatment prepared from a commercially available powder for infusion. Pharm Methods. 2012;3:1,1–1,3. doi: 10.4103/2229-4708.97700. PubMed DOI PMC

Pasparakis G, Bouropoulos N. Swelling studies and in vitro release of verapamil from calcium alginate and calcium alginate–chitosan beads. Int J Pharm. 2006;323(1):34–42. doi: 10.1016/j.ijpharm.2006.05.054. PubMed DOI

Pikal MJ. Freeze drying. In: Swarbrick J, editor. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker; 2002. pp. 1299–1326.

Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm. 2001;224(1):19–38. doi: 10.1016/S0378-5173(01)00720-7. PubMed DOI

Soares PI, Sousa AI, Silva JC, Ferreira IM, Novo CM, Borges JP. Chitosan-based nanoparticles as drug delivery systems for doxorubicin: optimization and modelling. Carbohydr Polym. 2016;147:304–312. doi: 10.1016/j.carbpol.2016.03.028. PubMed DOI

Srivastava G, Walke S, Dhavale D, Gade W, Doshi J, Kumar R, Doshi P. Tartrate/tripolyphosphate as co-crosslinker for water soluble chitosan used in protein antigens encapsulation. Int J Biol Macromolec. 2016;91:381–393. doi: 10.1016/j.ijbiomac.2016.05.099. PubMed DOI

Tian XH, Lin XN, Wei F, Feng W, Huang ZC, Wang P, Diao Y. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine. 2011;6:445–452. PubMed PMC

Tyndall EM, Draffan AG, Frey B, Pool B, Halim R, Jahangiri S, Thomas J. Prodrugs of imidazotriazine and pyrrolotriazine C-nucleosides can increase anti-HCV activity and enhance nucleotide triphosphate concentrations in vitro. Bioorg Med Chem Lett. 2015;25(4):869–873. doi: 10.1016/j.bmcl.2014.12.069. PubMed DOI

Wang H, Xu Y, Zhou X. Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation. Int J Mol Sci. 2014;15(3):3519–3532. doi: 10.3390/ijms15033519. PubMed DOI PMC

Wang Q, Liu P, Liu P, Gong T, Li S, Duan Y, Zhang Z (2014b) Preparation, blood coagulation and cell compatibility evaluation of chitosan-graft-polylactide copolymers. Biomed Mater 9(1):015007 PubMed

Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi: 10.1056/NEJMra0708126. PubMed DOI

Wheelhouse RT, Stevens MF. Decomposition of the antitumour drug temozolomide in deuteriated phosphate buffer: methyl group transfer is accompanied by deuterium exchange. J Chem Soc Chem Comm. 1993;15:1177–1178. doi: 10.1039/c39930001177. DOI

Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713–2722. doi: 10.1016/j.biomaterials.2004.07.050. PubMed DOI

Xu Y, Shen M, Li Y, Sun Y, Teng Y, Wang Y, Duan Y. The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells. Oncotarget. 2015;7:15. PubMed PMC

Xu Y, Shen M, Sun Y, Gao P, Duan Y (2016) Nano composite thermo-sensitive gel for paclitaxel and temozolomide co-delivery to glioblastoma cells. J Nanosci Nanotechnol 16(12):12288-12298 PubMed

You J, Li W, Yu C, Zhao C, Jin L, Zhou Y, Wang O. Amphiphilically modified chitosan cationic nanoparticles for drug delivery. JNR. 2013;15(12):1–10.

Zhang H, Gao S. Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. Int J Pharm. 2007;329(1):122–128. doi: 10.1016/j.ijpharm.2006.08.027. PubMed DOI

Zhu Y, Liao L. Applications of nanoparticles for anticancer drug delivery: a review. JNN. 2015;15(7):4753–4773. doi: 10.1166/jnn.2015.10298. PubMed DOI